Aurinia Pharmaceuticals (AUPH) Gross Margin (2020 - 2026)
Aurinia Pharmaceuticals posted quarterly Gross Margin of 91.63% for Q1 2026, up 535.0% year-on-year from 14.43% in Q1 2025, and up 3.43% on a QoQ basis from 88.59% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 7 years of Gross Margin data on file, last reported at 91.63% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 535.0% year-over-year to 91.63%; the trailing twelve-month figure through Mar 2026 stood at 89.74% (up 150.0% YoY), and the FY2025 full-year result was 88.46%, up 47.0% from the prior year.
- Gross Margin for Q1 2026 stood at 91.63%, up from 88.59% in the prior quarter.
- Across five years, Gross Margin topped out at 98.82% in Q1 2022 and bottomed at 84.42% in Q2 2024.
- The 5-year median for Gross Margin is 90.73% (2024), against an average of 91.21%.
- The widest annual swing landed in 2024, when Gross Margin plunged 1419 bps; it then jumped 541 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 95.21% in 2022, then fell by 8 bps to 88.04% in 2023, then gained by 3 bps to 90.73% in 2024, then slipped by 2 bps to 88.59% in 2025, then gained by 3 bps to 91.63% in 2026.
- The last three Gross Margin figures came in at 91.63% (Q1 2026), 88.59% (Q4 2025), and 88.87% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 82.22% |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 91.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.63% |
| Dec 31, 2025 | 88.59% |
| Sep 30, 2025 | 88.87% |
| Jun 30, 2025 | 89.84% |
| Mar 31, 2025 | 86.27% |
| Dec 31, 2024 | 90.73% |
| Sep 30, 2024 | 91.10% |
| Jun 30, 2024 | 84.42% |
| Mar 31, 2024 | 84.59% |
| Dec 31, 2023 | 88.04% |
| Sep 30, 2023 | 87.58% |
| Jun 30, 2023 | 96.23% |
| Mar 31, 2023 | 98.78% |
| Dec 31, 2022 | 95.21% |
| Sep 30, 2022 | 95.61% |
| Jun 30, 2022 | 94.33% |
| Mar 31, 2022 | 98.82% |
| Dec 31, 2021 | 97.94% |
| Sep 30, 2021 | 98.27% |
| Jun 30, 2021 | 95.35% |
| Mar 31, 2021 | 94.75% |
| Dec 31, 2020 | 100.00% |
| Sep 30, 2020 | 100.00% |
| Jun 30, 2020 | 100.00% |